ASND vs VRTX: fair value comparison
Ascendis Pharma A/S and Vertex Pharmaceuticals Incorporated · Updated 2026-10-19
ASND reports in EUR, so no same-currency fair-value verdict is published for it. Within Healthcare, VRTX currently ranks higher by quality score.
| ASND | VRTX | |
|---|---|---|
| Verdict | Awaiting full valuation | Fairly valued |
| Last price | $227.31 | $510.08 |
| 12-month range | $196.01–$277.18 | $409.47–$557.96 |
| Rank by discount to fair value | — | #70 of 108 Healthcare |
| Rank by quality score | #16 of 301 Healthcare | #14 of 301 Healthcare |
| Quality grade | A | A |
| Leverage | Low | Low |
| Margin trend | Expanding | Stable |
| Revenue growth | High | Strong |
| RSI zone | Neutral | Neutral |
| 50/200-day trend | Mixed | — |
| DCF cross-check | — | Overvalued |
| 52-week position | The lower-middle quarter | The upper-middle quarter |
Full single-stock breakdowns: ASND fair value analysis · VRTX fair value analysis